EE490 The Budget Impact of Zanubrutinib for the Treatment of Waldenstrom's Macroglobulinemia in the United States

Abstract

Waldenstrom’s macroglobulinemia (WM) is a rare B-cell malignancy of which Bruton tyrosine kinase (BTK) plays a critical role in B-cell receptor signaling. Zanubrutinib, a highly selective, next-generation BTK inhibitor was approved for the treatment of adult patients with WM in the United States (US) on August 31, 2021. This study aimed to estimate the budget impact of providing access to zanubrutinib for the treatment of adult patients with WM from the US healthcare payer perspective.